PMID- 36015100
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220830
IS  - 1424-8247 (Print)
IS  - 1424-8247 (Electronic)
IS  - 1424-8247 (Linking)
VI  - 15
IP  - 8
DP  - 2022 Jul 30
TI  - Continuous Subcutaneous Insulin Infusion (CSII) Combined with Oral 
      Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Network 
      Meta-Analysis of Randomized, Controlled Trials.
LID - 10.3390/ph15080953 [doi]
LID - 953
AB  - The clinical efficacy of continuous subcutaneous insulin infusion (CSII) therapy 
      combined with six classes of oral glucose-lowering drugs (GLDs) 
      (TZDs/metformin/acarbose/GLP-1 receptor agonist/SGLT-2 inhibitor/DPP-4 inhibitor) 
      was evaluated by a network meta-analysis to provide an evidence-based reference 
      in making a clinical decision on CSII combined with drugs in the treatment of 
      type 2 diabetes. Data were retrieved from eight databases: the Chinese Journal 
      Full-Text Database (CNKI), VIP Chinese Science and Technology Periodicals 
      Full-Text Database (VP-CSFD), Wanfang Data Journal Paper Resource (WANFANG), 
      China Biomedical Database (CBM), PubMed, Embase, Cochrane Library, and Web of 
      Science. The retrieval period dated from the library's construction to 27 June 
      2021. The search was for randomized, controlled trial studies (RCT) on insulin 
      infusion (CSII) combined with oral hypoglycemic drugs 
      (TZDs/metformin/acarbose/GLP-1 receptor agonist/SGLT-2 inhibitor/DPP-4 inhibitor) 
      in the treatment of type 2 diabetes. Quality evaluation and data extraction were 
      performed on the studies included, and network meta-analysis was performed with 
      R4.0.1 software. A total of 56 publications was included in the final network 
      meta-analysis, with a total sample size of 4395. Results based on the network 
      meta-analysis were that CSII combined with a metformin works best on fasting 
      blood glucose (FBG) and 2 h postprandial blood glucose (2hPG) and improves 
      insulin resistance (lower HOMA-IR levels). CSII combined with a DPP-4 inhibitor 
      had the best clinical effect in reducing glycosylated hemoglobin levels. 
      Treatment with CSII combined with a DPP-4 inhibitor was the fastest way to 
      achieve the blood glucose standard. In terms of insulin dosage, an insulin pump 
      (CSII) combined with the GLP-1 receptor agonist can significantly reduce insulin 
      dosage. Network meta-analysis evidence suggests that an insulin infusion (CSII) 
      combined with oral hypoglycemic drugs can improve clinical efficacy in 
      controlling blood sugar and improving insulin resistance, insulin dosage, and 
      standard time. However, the most outstanding performance was that of insulin 
      infusion (CSII) combined with metformin, which had the best clinical effect in 
      controlling blood sugar and improving insulin resistance.
FAU - Li, Hui
AU  - Li H
AD  - Department of endocrine, Traditional Chinese Medicine Hospital Affiliated to 
      Xinjiang Medical University, Urumqi 830000, China.
FAU - Yang, Aimin
AU  - Yang A
AUID- ORCID: 0000-0003-2968-1762
AD  - Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong 
      Kong 999077, China.
FAU - Zhao, Shi
AU  - Zhao S
AUID- ORCID: 0000-0001-8722-6149
AD  - JC School of Public Health and Primary Care, Chinese University of Hong Kong, 
      Hong Kong 999077, China.
FAU - Chow, Elaine Yk
AU  - Chow EY
AD  - Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong 
      Kong 999077, China.
FAU - Javanbakht, Mohammad
AU  - Javanbakht M
AUID- ORCID: 0000-0002-0837-9591
AD  - Nephrology and Urology Research Center, Baqiyatallah University of Medical 
      Sciences, Tehran 1435916471, Iran.
FAU - Li, Yinhui
AU  - Li Y
AD  - Department of endocrine, Traditional Chinese Medicine Hospital Affiliated to 
      Xinjiang Medical University, Urumqi 830000, China.
FAU - Lin, Dandan
AU  - Lin D
AD  - Department of Medical Engineering and Technology, Xinjiang Medical University, 
      Urumqi 830011, China.
FAU - Xu, Lijuan
AU  - Xu L
AD  - Department of endocrine, Traditional Chinese Medicine Hospital Affiliated to 
      Xinjiang Medical University, Urumqi 830000, China.
FAU - Zang, Deng
AU  - Zang D
AD  - Department of endocrine, Traditional Chinese Medicine Hospital Affiliated to 
      Xinjiang Medical University, Urumqi 830000, China.
FAU - Wang, Kai
AU  - Wang K
AUID- ORCID: 0000-0002-6224-8453
AD  - Department of Medical Engineering and Technology, Xinjiang Medical University, 
      Urumqi 830011, China.
FAU - Ma, Li
AU  - Ma L
AD  - Department of endocrine, Traditional Chinese Medicine Hospital Affiliated to 
      Xinjiang Medical University, Urumqi 830000, China.
LA  - eng
GR  - 2020D14020/Kai Wang/
GR  - 11961071/Kai Wang/
PT  - Journal Article
PT  - Review
DEP - 20220730
PL  - Switzerland
TA  - Pharmaceuticals (Basel)
JT  - Pharmaceuticals (Basel, Switzerland)
JID - 101238453
PMC - PMC9412496
OTO - NOTNLM
OT  - RCT
OT  - insulin infusion (CSII)
OT  - network meta-analysis
OT  - oral hypoglycemic drugs
OT  - type 2 diabetes
COIS- The authors declare no conflict of interest.
EDAT- 2022/08/27 06:00
MHDA- 2022/08/27 06:01
PMCR- 2022/07/30
CRDT- 2022/08/26 01:41
PHST- 2022/06/08 00:00 [received]
PHST- 2022/07/13 00:00 [revised]
PHST- 2022/07/24 00:00 [accepted]
PHST- 2022/08/26 01:41 [entrez]
PHST- 2022/08/27 06:00 [pubmed]
PHST- 2022/08/27 06:01 [medline]
PHST- 2022/07/30 00:00 [pmc-release]
AID - ph15080953 [pii]
AID - pharmaceuticals-15-00953 [pii]
AID - 10.3390/ph15080953 [doi]
PST - epublish
SO  - Pharmaceuticals (Basel). 2022 Jul 30;15(8):953. doi: 10.3390/ph15080953.